

THC Form 7

MONTHLY PROGRESS REPORT

August

Name of CSE Issuer **THC Biomed Intl Ltd.**
Trading Symbol: **THC**
Number of Outstanding Listed Securities **152,867,404 common shares and 48,818,697 reserved for Issuance**
Date: **September 6, 2019**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company announced it closed a non-brokered private placement of convertible debentures for gross proceeds of \$642,679.09 (the "Debenture"). Dated August 16, 2019, the term of the Debenture is 12 months and bears interest at 8% per annum calculated on an annual basis and payable semi-annually in arrears. The Debenture is convertible into common shares at a price of \$0.25 per share, at any time at the election of the holder.

The proceeds of the Debenture will be used by the Company towards funding the continuous growth and expansion of the Company as well as general working capital

2. Provide a general overview and discussion of the activities of management.

None

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Company closed a non-brokered private placement of convertible debentures for gross proceeds of \$642,679.09 (the "Debenture"). Dated August 16, 2019, the term of the Debenture is 12 months and bears interest at 8% per annum calculated on an annual basis and payable semi-

annually in arrears. The Debenture is convertible into common shares at a price of \$0.25 per share, at any time at the election of the holder.

The proceeds of the Debenture will be used by the Company towards funding the continuous growth and expansion of the Company as well as general working capital

None.

14. Provide details of any securities issued and options or warrants granted.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Company's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Company's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at www.sedar.com.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: September 6, 2019.

John Miller

Name of Director or Senior Officer

"John Miller"

Signature

President and CEO

Official Capacity

Issuer Details		
Name of Issuer: THC Biomed Intl Ltd.	For Month End August	Date of Report: YYYYMMDD 2019/09/06
Issuer Address: P.O. Box 20033 Towne Centre		
City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. (250) 870-2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. (250) 870-2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	